• Global trial demonstrates some benefits

    From ScienceDaily@1:317/3 to All on Monday, April 04, 2022 22:30:42
    Global trial demonstrates some benefits of flu shots for heart failure patients
    Study did not meet its primary endpoints, but rates of cardiovascular
    events were significantly lower during peak flu season

    Date:
    April 4, 2022
    Source:
    American College of Cardiology
    Summary:
    People with heart failure who received an annual flu shot had lower
    rates of pneumonia and hospitalization on a year-round basis and
    a reduction in major cardiovascular events during peak flu season,
    in a new study.

    However, the trial did not meet its primary endpoint as patients
    who received the flu vaccine showed no significant reduction in
    rates of major cardiovascular events on a year-round basis during
    the study's three-year follow-up period.



    FULL STORY ========================================================================== People with heart failure who received an annual flu shot had lower
    rates of pneumonia and hospitalization on a year-round basis and a
    reduction in major cardiovascular events during peak flu season, in
    a study presented at the American College of Cardiology's 71st Annual Scientific Session. However, the trial did not meet its primary endpoint
    as patients who received the flu vaccine showed no significant reduction
    in rates of major cardiovascular events on a year-round basis during
    the study's three-year follow-up period.


    ==========================================================================
    The study is the first randomized controlled trial to assess the benefits
    of the flu vaccine specifically in people with heart failure, who face
    a high risk of cardiovascular events. It was conducted in countries
    across Asia, Africa and the Middle East where getting a flu shot is
    not routine for most people. The trial did not meet its primary or
    co-primary endpoints, which focused on the rate of major cardiovascular
    events analyzed on a year-round basis. A prespecified sub-analysis of the
    data revealed that people who received a flu shot showed a significant reduction in cardiovascular events during periods of the year when rates
    of influenza were highest.

    "Although our prespecified endpoints were not significant, our data
    suggest that there's a clinical benefit [to getting a flu shot] given
    the clear reduction in pneumonia, moderate reduction in hospitalization
    and reduction in vascular events and deaths during periods of peak
    influenza," said Mark Loeb, MD, Michael G. DeGroote chair in infectious diseases at McMaster University in Ontario, Canada, and the study's
    lead author. "When taken together with previous trials and observational studies, the collective data demonstrate there is a substantial benefit
    to receiving a flu vaccine for people with heart failure." Heart failure
    is a condition in which the heart becomes too weak or stiff to pump blood effectively. Previous studies have shown that people with heart disease
    or cardiovascular risk factors face an elevated risk of complications
    when they contract influenza, but there has been a lack of evidence
    on whether flu vaccines can help to mitigate this risk specifically in
    people with heart failure.

    The trial enrolled 5,129 patients with heart failure in 10 countries
    where flu vaccines are not common. Participants did not routinely get
    flu shots and had previously received a flu shot no more than once during
    the three years preceding the trial. Participants were randomly assigned
    to receive a flu shot or a placebo annually for up to three years, though
    they were also allowed to get a flu shot outside of the trial. Researchers tracked health outcomes for a median of 2.9 years. The trial's primary
    endpoint was a composite of death from cardiovascular causes, non-fatal
    heart attack or non-fatal stroke. Its co- primary endpoint included a
    composite of any of these events plus hospitalization for heart failure.

    Overall, the composite primary endpoint occurred in 691 participants and
    1,470 experienced the composite co-primary endpoint. When analyzed on a year-round basis there was no significant difference in the rates of these events between those who had received a flu vaccine and those who had not.



    ========================================================================== However, separate analyses of hospitalization, pneumonia and other
    respiratory outcomes found that rates of pneumonia were 42% lower and hospitalizations were 15% lower among those who received a flu shot.

    Researchers also found a significant reduction in the first primary
    endpoint - - as well as reductions in all-cause death and cardiovascular
    death -- in favor of the flu vaccine when the analysis was limited
    to periods of peak influenza circulation. In contrast, there was no
    significant difference in these endpoints between groups during periods
    of the year when influenza circulation was low.

    Based on these results, researchers said the flu vaccine did help to
    protect patients from influenza complications, including cardiovascular
    events.

    "Many of the effects we found during peak flu circulation disappeared
    outside of it," Loeb said. "There's no biological explanation for that
    other than influenza infections." While influenza circulation tends
    to rise and fall throughout the year, peaks do not always occur at the
    same time each year in places close to the equator the way they do in
    places that have marked temperature changes between winter and summer,
    such as the U.S. Because many of the countries included in the study lack active disease surveillance systems, researchers used the best evidence available to determine when the peak period of influenza circulation
    occurred in each location.

    While the study was conducted in countries where the flu vaccine is
    either not widely available or not common to receive, Loeb said the
    results could likely be generalizable even in Western countries where
    flu vaccine uptake is higher.

    Study participants were allowed to get a flu vaccine outside of the study,
    but Loeb said that only a very small fraction did, so this likely had
    no effect on the study findings. He added that the study was stopped
    early in four countries due to the COVID-19 pandemic.

    Loeb said that additional trials and large-scale observational studies
    could further clarify the health benefits of influenza vaccination in
    people with cardiovascular disease.

    "I think this study offers an important message about vaccines generally -
    - that it is important to do randomized controlled trials in populations
    that historically haven't had a very high uptake of vaccines," Loeb
    said. "These types of [research] gaps have to be filled." The study
    was funded by the Joint Global Health Trials Scheme, which in turn
    is funded by the U.K. Department for International Development, the
    Medical Research Council, the National Institute for Health Research,
    the Wellcome Trust and the Canadian Institutes for Health Research.


    ========================================================================== Story Source: Materials provided by American_College_of_Cardiology. Note: Content may be edited for style and length.


    ==========================================================================


    Link to news story: https://www.sciencedaily.com/releases/2022/04/220404105743.htm

    --- up 5 weeks, 10 hours, 51 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)